75.56% 0.0068

Nls Pharmaceutics Ag (NLSPW)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Nls Pharmaceutics Ag Stock (NLSPW) Company Profile

Nls Pharmaceutics Ag

Healthcare (1195)

Biotechnology (683)

41 44 512 21 50

The Circle 6, Zurich

Nächster Verdiensttermin

Neueste SEC-Einreichungen

NLSPW's Discussions on Twitter

Vergleichen Sie NLSPW mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NLSPW	0.0158	0	0	0	0	0.00
VRTX	449.33	115.43B	10.63B	-479.80M	-1.35B	13.33
REGN	749.22	82.04B	13.85B	4.65B	3.32B	35.06
ARGX	588.35	35.30B	1.86B	-40.29M	-1.28B	-4.16
ALNY	247.58	32.04B	2.09B	-332.26M	16.06M	-4.14
BNTX	106.96	24.89B	3.30B	-501.07M	1.03B	11.54

Nls Pharmaceutics Ag Aktie (NLSPW) Neueste Nachrichten

Finanzdaten der Nls Pharmaceutics Ag-Aktie (NLSPW)

Es liegen keine Finanzdaten für Nls Pharmaceutics Ag (NLSPW) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Nls Pharmaceutics Ag (NLSPW)

Nls Pharmaceutics Ag Stock (NLSPW) Company Profile

Vergleichen Sie NLSPW mit anderen Aktien

Nls Pharmaceutics Ag Aktie (NLSPW) Neueste Nachrichten

NLS Pharmaceutics Unveils Promising Narcolepsy Treatment - TipRanks

NLS Pharmaceutics highlights preclinical program for AEX-41, AEX-2 - TipRanks

NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders - AccessWire

NLS Pharmaceutics Advances Novel Dual Orexin Drug Platform in Key Preclinical Study | NLSPW Stock News - StockTitan

NLS Pharmaceutics AG Announces Share Capital Expansion - TipRanks

NLSP stock touches 52-week low at $3.15 amid market challenges - Investing.com

500: Something went wrong - Investing.com India

Kadimastem Ltd. Faces Financial Uncertainty - TipRanks

NLS Pharmaceutics announces merger with Kadimastem By Investing.com - Investing.com UK

NLS Pharmaceutics Announces Strategic Capital Restructuring - TipRanks

NLS and Kadimastem stocks soar following merger agreement - Yahoo Finance

NLS Pharmaceutics and Kadimastem to merge in biotech deal - Investing.com India

NLS Pharmaceutics and Kadimastem to merge in biotech deal By Investing.com - Investing.com UK

NLS Pharmaceutics stock jumps 50% on merger agreement with cell therapy firm Kadimastem - Seeking Alpha

NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement - AccessWire

NLS Pharmaceutics Merges with Kadimastem for Strategic Growth - TipRanks

NLSP stock touches 52-week low at $4 amid sharp annual decline - Investing.com Nigeria

NLSP stock touches 52-week low at $4 amid sharp annual decline By Investing.com - Investing.com South Africa

NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements - AccessWire

U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.03% - MSN

NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence - AccessWire

NLS Pharmaceutics Sees Reduced Losses Amid Financial Challenges - Yahoo Finance

NLS Pharmaceutics announces expected compliance with Nasdaq listing rules - TipRanks

NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules - AccessWire

NLS Pharmaceutics Launches New Share Purchase Warrant - TipRanks

NLS Pharmaceutics Regains Nasdaq Compliance - TipRanks

NLS Pharmaceutics AG announced that it expects to receive $3.201614 million in funding - Marketscreener.com

NLS Pharmaceutics Shareholders Approve Agenda - TipRanks

NLS Pharmaceutics Signs Option Agreement to Acquire Rights to Aexon Labs' Assets; Shares Rise - Marketscreener.com

NLS Pharmaceutics Receives Nasdaq Compliance Extension - TipRanks

NLSP stock touches 52-week high of $4.61 amid market fluctuations - Investing.com

NLS Pharmaceutics announces 1-for-40 reverse stock split - Investing.com

NLS Pharmaceutics Outlines Capital and Share Strategy - TipRanks

NLS Pharmaceutics announces 1-for-40 reverse share split - TipRanks

NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split - AccessWire

BREAKING: NPA to ballot pharmacists on working to rule - The Pharmacist

Novo Nordisk Inks $600M Genetic Medicines Pact With Canadian Firm To Target Cardiometabolic Indications - Yahoo Finance

Newell Brands Inc. (NASDAQ:NWL) Shares Bought by Primecap Management Co. CA - MarketBeat

National Beverage: Growth Fizzing Out With Questionable Earnings Quality - Seeking Alpha

London NHS trust paid out more than £1.3m in mental health claims in 5years - Time 107.5

North East London NHS trust pays out £1.3m in mental health negligence cases - Waltham Forest Echo

Keeping an Eye on Newell Brands Inc (NWL) After Insider Trading Activity - Knox Daily

GSK Velu’s Neuberg Diagnostics in talks with 360One, M&G Investments for $100 mn pre-IPO fundraise - Moneycontrol

Newell Brands Inc. (NASDAQ:NWL) Shares Bought by Arizona State Retirement System - Defense World

RSV medication among new Pharmac funding options - RNZ

NLS Pharmaceutics Plans Capital Increase and Debt Restructuring - TipRanks

Investor’s Toolkit: Key Ratios for Assessing NLS Pharmaceutics Ltd (NLSP)’s Performance - The Dwinnex

How To Buy NLS Pharmaceutics AG Stock Online in August 2024 - Traders Union

NLS Pharmaceutics (NASDAQ:NLSP) Trading 4.3% Higher - Defense World

NLS Pharmaceutics Gains PwC’s Endorsement - TipRanks

Crude Oil Moves Lower; NLS Pharmaceutics Shares Jump - MSN

Finanzdaten der Nls Pharmaceutics Ag-Aktie (NLSPW)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie NLSPW